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Abstract
Background: There has been no systematic evaluation of the association between genetic variants of type 2
receptor for TNFa (TNFR2) and type 2 diabetes, despite strong biological evidence for the role of this receptor in
the pathogenesis of this complex disorder. In view of this, we performed a comprehensive association analysis of
TNFRSF1B variants with type 2 diabetes in 4,200 Indo-European subjects from North India.
Methods: The initial phase evaluated association of seven SNPs viz. rs652625, rs496888, rs6697733, rs945439,
rs235249, rs17883432 and rs17884213 with type 2 diabetes in 2,115 participants (1,073 type 2 diabetes patients and
1,042 control subjects). Further, we conducted replication analysis of three associated SNPs in 2,085 subjects (1,047
type 2 diabetes patients and 1,038 control subjects).
Results: We observed nominal association of rs945439, rs235249 and rs17884213 with type 2 diabetes (P < 0.05) in
the initial phase. Haplotype CC of rs945439 and rs235249 conferred increased susceptibility for type 2 diabetes [OR =
1.19 (95%CI 1.03-1.37), P = 0.019/Pperm = 0.076] whereas, TG haplotype of rs235249 and rs17884213 provided
protection against type 2 diabetes [OR = 0.83 (95%CI 0.72-0.95, P = 7.2 × 10
-3/Pperm = 0.019]. We also observed
suggestive association of rs496888 with plasma hsCRP levels [P = 0.042]. However, the association of rs945439,
rs235249 and rs17884213 with type 2 diabetes was not replicated in the second study population. Meta-analysis of
the two studies also failed to detect any association with type 2 diabetes.
Conclusions: Our two-stage association analysis suggests that TNFRSF1B variants are not the determinants of
genetic risk of type 2 diabetes in North Indians.
Background
Low-grade systemic inflammation plays a crucial role in
the manifestation of type 2 diabetes [1]. Activation of
TNF-TNFR axis in response to elevated Tumor Necrosis
Factor a (TNFa) levels, a pro-inflammatory cytokine, can
be speculated to contribute to the causation of type 2 dia-
betes. TNFa which is involved in varied processes such
as inflammatory, immune and metabolic events, is over-
expressed in adipose and muscle tissues of obese and
type 2 diabetic subjects [2-4]. The metabolic activities of
TNFa a r em a i n l ym e d i a t e dt h r o u g hT N F R 2( t y p e2
receptor for TNFa), providing the inflammation-
metabolic interface in type 2 diabetes.
Enhanced TNFR2 expression and soluble TNFR2
(sTNFR2) levels have been observed in obesity, insulin
resistance and cardiovascular diseases [5-7]. While genetic
variants of TNFRSF1B (TNFR2 gene) have been shown to
be associated with various metabolic and inflammatory dis-
orders [8-11], the investigations were limited to only two
polymorphisms-M196R (rs1061622) and (CA)n repeat
polymorphism. These two polymorphisms have not been
analyzed extensively for their influence on the risk of type
2 diabetes. Only a solitary report suggested association of
(CA)n repeat polymorphism of TNFRSF1B with diabetic
neuropathy [9], while another study refuted its role in type
2 diabetes [12]. Moreover, the only study that investigated
M196R failed to provide evidence for its association with
type 2 diabetes [12]. Recently, we also investigated the
association of these well-studied common polymorphisms
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betes in North Indian population but did not find any
significant association [13].
The inconsistent reports suggest that the role of
TNFRSF1B variants in the pathogenesis of type 2 diabetes
is not clear yet, necessitating comprehensive evaluation
of TNFRSF1B variants. In view of this, we performed
association analysis of seven SNPs of TNFRSF1B with
type 2 diabetes in Indo-Europeans, followed by a replica-
tion analysis of three SNPs in an independent study
population of Indo-European subjects from North India.
Methods
Subjects
A total of 4,200 unrelated Indo-European subjects
including 2,120 patients with type 2 diabetes and 2,080
non-diabetic controls from two independent study popu-
lations from North India participated in the study. For
the initial association analysis, we recruited 2,115 subjects
comprising 1,073 patients with type 2 diabetes and 1,042
non-diabetic controls. Replication was assessed in an
independent study population of 2,085 individuals
including 1,047 type 2 diabetes patients and 1,038 control
subjects. The subjects in both the study populations were
recruited according to the inclusion and exclusion cri-
teria described previously [14]. Briefly, patients with type
2 diabetes diagnosed according to World Health Organi-
zation criteria [15]. The non-diabetic control samples
were collected by organizing ‘Diabetes Awareness Camps’
in the urban regions in and around Delhi from North
India. Subjects of ≥40 years of age with no family history
of diabetes in first and/or second degree relatives who
had glycated haemoglobin (HbA1c) level ≤6.0% and fast-
ing glucose level <110 mg/dL were recruited as controls.
All the participants provided written informed consent.
The study was approved by the Ethics Committees of the
participating institutions and was in accordance with the
principles of the Helsinki Declaration.
Anthropometric and biochemical measurements
Anthropometric and biochemical parameters related to
type 2 diabetes were measured in type 2 diabetic patients
and control subjects. Height, weight, waist circumference
and hip circumference were measured following standard
guidelines. Body mass index (BMI) and waist-to-hip ratio
(WHR) were calculated from these measurements. Levels
of glucose, HbA1c, insulin, C-peptide, total cholesterol,
triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C),
urea, uric acid and creatinine were measured as described
earlier [14]. Levels of hsCRP were estimated using either
ELISA (Biocheck Inc., CA, USA) or Cobas Integra 400
Plus (Roche Diagnostic, Mannheim, Germany). The
homeostasis model assessment of insulin resistance
(HOMA-IR) index was calculated as described earlier [16].
SNP selection and Genotyping
We first determined linkage disequilibrium (LD) pattern
and tag SNPs for TNFRSF1B using European population
data (HapMap 2). Four tag SNPs or their proxy SNPs
(prioritized based on their locations in functionally signifi-
cant region) that captured most of the SNPs in the gene
(rs496888, rs6697733, rs945439 and rs235249) were
selected. One tag SNP (rs3397) had already been geno-
typed in same sample set in our previous study [13]. Tag
SNPs not capturing other SNPs were avoided; instead
SNPs in functionally significant regions (promoter and
coding regions) considering spacing between the SNPs to
cover the entire gene were preferred (rs652625,
rs17883432 and rs17884213). With the present seven
SNPs and two SNPs (rs1061622 and rs3397) from our pre-
vious study, we captured 63% of all the variants reported
in HapMap for Caucasian population. A pictorial repre-
sentation of the selected SNPs along with gene structure
and LD pattern around TNFRSF1B in GIH (Gujarati
Indians in Houston, Texas) population from HapMap data
is provided in Additional file 1.
We genotyped seven SNPs-rs652625 (5’ flank), rs496888
(intron 1), rs6697733 (intron 1), rs945439 (exon 2),
rs235249 (intron 8), rs17883432 (exon 9) and rs17884213
(intron 9) for the initial association analysis. Genotyping
was performed using GoldenGate assay on Illumina plat-
form (Illumina Inc., San Diego, CA, USA). The genotyping
data obtained was subjected to extensive quality control as
provided in detail earlier [17]. Two SNPs (rs235249 and
rs17883432) failed in Illumina assay and were genotyped
using iPLEX on a MassARRAY System (Sequenom, San
Deigo, CA, USA). The SNPs that passed Illumina quality
control had an average call rate of 99% with concordance
of >99.9% in genotype calls in 7% duplicates. The average
genotyping success rate for SNPs genotyped on Sequenom
was >95% with 100% concordance rate in 4% duplicates.
In the replication phase, genotyping of rs945439, rs235249
and rs17884213 was performed using iPLEX on a Mas-
sARRAY System (Sequenom). These SNPs had average
call rate of 96% with 100% consistency of genotype calls in
5% duplicates.
Statistical Analysis
The statistical analyses were mainly performed using
PLINK v. 1.07 [http://pngu.mgh.harvard.edu/~purcell/
plink; [18]] or otherwise specified. Deviation from
Hardy Weinberg Equilibrium (HWE) was tested using
c
2 analysis. Association of SNPs with type 2 diabetes
was assessed using logistic regression analysis adjusted
for age, sex and BMI. Meta-analysis was performed by
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both under random and fixed effect models. Associa-
tion between genotypes and quantitative traits were
determined only in control subjects using Kruskal-
Wallis test using SPSS version 17.0. Pairwise LD
between the SNPs was determined using Haploview
4.0 and the haplotype blocks were defined using
the method of Gabriel et al., 2002 as implemented in
Haploview V4.0 [19]. Haplotype association analysis
adjusted for age, sex and BMI were carried out at
10,000 permutations. A P value < 0.017 was considered
significant after Bonferroni correction (P = 0.05/3) in
the replication analysis. Statistical power of the study
was determined using Quanto software (http://hydra.
usc.edu/gxe/) assuming log additive model of inheri-
tance and 10% prevalence of type 2 diabetes at a =
0.05. The initial and combined phase of the study had
82% and 98% power respectively to detect the associa-
tion of a SNP with OR of 1.25 and allele frequency of
0.19 (the least allele frequency for the present study).
Results
The anthropometric and biochemical characteristics of
patients with type 2 diabetes and control subjects in two
s t u d yp o p u l a t i o n sa r ep r o v i d e di nT a b l e1 .O ft h es e v e n
SNPs, rs652625 and rs17883432 had minor allele fre-
quency (MAF) <5.0% and were excluded from subsequent
association analysis. The genotypic distributions of the
polymorphisms were in accordance with HWE both
among type 2 diabetes patients and controls (all P > 0.047)
(see Additional file 2).
In the initial phase, we observed nominal association of
three SNPs- rs945439, rs235249 and rs17884213 with type
2 diabetes at P < 0.05 (Table 2). Stronger association was
observed under recessive model for rs17884213 and
rs235249. Individuals who were homozygous for minor
allele of rs17884213 and rs235249 had OR of 1.80 (95%CI
1.25-2.60, P =1 . 7×1 0
-3) and 1.69 (95%CI 1.17-2.46, P =
5.7 × 10
-3) respectively, under recessive model. Other
genetic variants studied here-rs496888 and rs6697733
both in intron 1, did not show association with type 2 dia-
betes in the initial study population.
SNP rs945439 was found to be in LD with rs235249
(D’ =0 . 9 2a n dr
2 = 0.83) (Figure 1). The haplotype CC
containing minor alleles of these two SNPs was asso-
ciated with increased susceptibility for type 2 diabetes
with OR of 1.19 (95%CI 1.03-1.37, P =0 . 0 1 9 / Pperm =
0.076) (Table 3). We also observed some extent of LD
between rs235249 and rs17884213 (D’ = 0.83, r
2 = 0.66).
Haplotype TG encompassing major alleles of rs235249
and rs17884213 was associated with protection against
type 2 diabetes with OR of 0.83 (95%CI 0.72-0.95, P =
7.2 × 10
-3). The association remained significant after
performing 10,000 permutations (Pperm = 0.019).
Table 1 Anthropometric and clinical characteristics of the study populations
Initial phase Replication phase
Characteristics Type 2 diabetes patients Control
Subjects
Type 2 diabetes patients Control
subjects
N (Men/Women) 1019 (592/427) 1006 (606/400) 1047 (619/428) 1038 (516/522)
Age (years) 53 (45-62) 50 (44-60) 55 (49-62) 54 (45-64)
BMI (Kg/m
2)
Men 23.8 (22.0-26.0) 23.1 (20.1-25.7) 24.8 (22.7-27.8) 24.7 (22.3-27.4)
Women 26.7 (24.2-29.2) 25.0 (21.1-28.5) 27.4 (24.6-30.6) 26.4 (23.1-29.3)
WHR
Men 1.00 (0.97-1.03) 0.97 (0.92-1.0) 0.98 (0.95-1.03) 0.97 (0.93-1.01)
Women 1.00 (0.97-1.03) 0.86 (0.82-0.92) 0.93 (0.87-0.97) 0.86 (0.82-0.90)
Systolic BP (mmHg) 130 (130-140) 120 (112-132) 130 (122-140) 130 (120-140)
Diastolic BP (mmHg) 80 (78-90) 80 (70-88) 82 (80-90) 80 (78-90)
HbA1c (%) 7.8 (6.5-9.4) 5.2 (4.9-5.6) 8.2 (6.9-9.6) 5.6 (5.3-5.9)
FPG (mmol/L) 7.9 (6.4-10.3) 4.9 (4.5-5.3) 7.8 (6.2-10.3) 4.9 (4.4-5.3)
FPI (pmol/L) 82.8 (42.0-166.8) 32.4 (17.4-57.6) 74.4 (26.0-96.0) 43.8 (28.2-63.6)
HOMA-IR 5.20 (2.30-9.60) 1.20 (0.60-2.00) 4.30 (2.30-9.30) 1.60 (1.00-2.40)
C-peptide (nmol/L) 0.89 (0.56-1.36) 0.53 (0.36-0.73) 1.05 (0.69-1.60) 0.66 (0.50-0.86)
hsCRP (mg/L) 2.20 (0.90-4.70) 1.30 (0.60-3.00) 1.86 (0.90-3.44) 1.61 (0.90-3.04)
TC (mmol/L) 4.20 (3.50-5.00) 4.40 (3.7-5.10) 4.64 (3.86-5.42) 4.91 (4.22-5.52)
LDL-C (mmol/L) 2.57 (1.99-3.36) 2.79 (2.33-3.41) 2.73 (2.10-3.42) 3.01 (2.49-3.51)
HDL-C (mmol/L) 1.03 (0.88-1.22) 1.06 (0.88-1.28) 1.11 (0.94-1.34) 1.24 (1.06-1.46)
TG (mmol/L) 1.60 (1.10-2.20) 1.30 (1.00-1.80) 1.43 (0.98-2.13) 1.22 (0.86-1.64)
Data are median values with interquartile ranges in parentheses. WHR: waist-hip ratio; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-IR:
homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triglyceride
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Page 3 of 8Table 2 Association analysis of TNFRSF1B SNPs with type 2 diabetes in Indo-European population from North India
Initial phase Replication phase Meta-analysis
Genotype distribution Genotype distribution
SNP Type 2 diabetes patients Control
Subjects
OR
(95%CI)
P Type 2 diabetes patients Control
Subjects
OR
(95%CI)
P OR
r/
OR
f
P
r/
P
f
rs496888 (A/G)*
(Intron 1)
669 (66.0)
299 (29.6)
45 (4.4)
642 (64.5)
314 (31.5)
40 (4.0)
0.95
(0.81-1.11)
0.484
rs6697733 (T/C)*
(Intron 1)
536 (52.8)
404 (39.7)
76 (7.5)
544 (54.1)
400 (39.9)
61 (6.0)
1.07
(0.93-1.24)
0.346
rs945439 (T/C)
(Exon 2)
540 (53.3)
395 (38.8)
80 (7.9)
566 (56.3)
386 (38.5)
53 (5.3)
1.17
(1.01-1.36)
0.036 546 (54.0)
393 (38.9)
72 (7.1)
523 (52.2)
404 (40.3)
75 (7.5)
0.94
(0.81-1.08)
0.364 1.05/1.04 0.686/0.420
rs235249 (T/C)
(Intron 8)
503 (51.6)
392 (40.2)
80 (8.2)
545 (55.6)
385 (39.2)
51 (5.2)
1.22
(1.05-1.41)
0.010 561 (54.6)
391 (38.1)
75 (7.3)
536 (53.1)
399 (39.5)
75 (7.4)
0.95
(0.82-1.09)
0.440 1.07/1.06 0.583/0.227
rs17884213 (G/A)
(Intron 9)
550 (54.3)
376 (37.0)
88 (8.7)
564 (56.1)
390 (38.9)
50 (5.0)
1.17
(1.02-1.36)
0.031 569 (56.7)
373 (37.1)
62 (6.2)
525 (53.0)
407 (41.1)
58 (5.9)
0.92
(0.80-1.07)
0.289 1.04/1.04 0.733/0.432
Association was assessed assuming additive model adjusted for age, sex and BMI. The significant associations are highlighted in bold text. OR: odds ratio; CI: confidence interval; OR
r: odds ratio for random effects
meta-analysis; OR
f: odds ratio for fixed effects meta-analysis. * SNPs not genotyped in the replication phase.
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8We then investigated the effect of TNFRSF1B poly-
morphisms on quantitative metabolic traits related to type
2 diabetes viz BMI, WHR, HbA1c, fasting glucose, insulin,
C-peptide, total cholesterol, TG, HDL-C, LDL-C, urea,
uric acid and creatinine (Table 4). For this, the clinical
variables of only control subjects were compared across
the genotypes of the SNPs. We observed suggestive asso-
ciation of rs496888 with plasma hsCRP levels (P = 0.042).
No influence of other variants on any of the metabolic
traits investigated was found.
Further, we attempted to replicate the associations of
rs945439, rs235249 and rs17884213 in an independent
study population of 2,085 Indo-European subjects. We
did not find significant association of any of these SNPs
with type 2 diabetes in the replication study population
(P = 0.364, 0.440 and 0.289 respectively). We also per-
formed meta-analysis of two studies that failed to iden-
tify any association with type 2 diabetes (Table 2).
Discussion
India has the largest number of individuals suffering from
type 2 diabetes, with the prevalence likely to increase to
approximately 80 million over the next two decades [20].
The factors contributing to such a high risk of type 2 dia-
betes in this part of world are not clearly understood yet.
Previously, we demonstratedr o l eo fi n f l a m m a t i o ni n
the development of type 2 diabetes in Indo-European
population [21]. Our group also showed association of
TNF-LTA locus variants with type 2 diabetes in this
population [22]. This suggests TNFRSF1B as an impor-
tant biological candidate gene for type 2 diabetes in
Indo-Europeans.
Previously, we investigated association of three
TNFRSF1B polymorphisms- rs1061622 (M196R; exon6),
rs3397 (3’UTR) and (CA)n a n dd e m o n s t r a t e dt h a tt h e s e
polymorphisms are not associated with type 2 diabetes or
its complications in Indo-Europeans [13]. Here, we carried
out a comprehensive association analysis of TNFRSF1B
variants with type 2 diabetes in Indo-Europeans.
In the initial phase, we observed nominal association of
rs235249 in intron 8 and rs17884213 in intron 9 with
type 2 diabetes. Also, haplotype TG, harboring major
a l l e l e so ft h e s et w oS N P sw a sassociated with protection
against type 2 diabetes. SNP rs945439, a synonymous
Figure 1 Pairwise linkage disequilibrium between the selected SNPs in TNFRSF1B.( A )P l o tw i t hD ’ values; (B) Plot with r
2values between the SNPs.
Table 3 Association of haplotypes of TNFRSF1B with type 2 diabetes in North Indian population
Initial phase Replication phase
SNPs Haplotype Type 2 diabetes patients Control
Subjects
OR
(95%CI)
P
Pperm
Type 2 diabetes patients Control
Subjects
OR
(95%CI)
P
Pperm
rs235249
rs17884213
TG 0.683 0.721 0.83
(0.72-0.95)
7.6 × 10
-3
0.021
0.701 0.688 1.05
(0.92-1.20)
0.354
0.743
rs945439
rs235249
CC 0.261 0.230 1.19
(1.03-1.37)
0.019
0.076
0.247 0.259 0.93
(0.81-1.07)
0.353
0.755
OR: odds ratio; CI: confidence interval; Pperm: P values obtained after performing 10,000 permutations.
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tion with type 2 diabetes in the initial phase. In spite of
being a coding variation, this SNP had never been evalu-
ated for its role in the manifestation of any metabolic dis-
order. SNPs rs496888 and rs6697733 both in intron 1,
did not influence the susceptibility to type 2 diabetes in
the study population.
The investigation of the association of genetic variants
of TNFRSF1B with quantitative traits revealed only the
nominal association of rs496888 with hsCRP levels.
Hence, being a pro-inflammatory gene, we did observe a
nominal association with inflammation. No association of
other variants with any other metabolic traits suggests
that either these associated SNPs have very small effect
o nt h eq u a n t i t a t i v et r a i t sa n a l y z e dh e r eo rt h e ym i g h t
modulate the risk of type 2 diabetes by influencing some
other biochemical traits not investigated here.
The observed differences in the results of initial and
replication phases might reflect the heterogeneity in the
population. However, subjects in both the study popula-
tions have been collected with great caution regarding eth-
nicity and geographical regions and form a homogenous
cluster as reported by the Indian Genome Variation Con-
sortium [23]. This strategy though cannot completely rule
out but decreases the effects of population stratification.
Importantly, a study by Rosenberg et al [24] has stated
that false positives arising due to genetic heterogeneity in
the diverse Indian population could be smaller than
expected. It is pertinent to mention here that in our recent
study we successfully replicated the association of top
eight GWAS confirmed loci with type 2 diabetes in the
same population [17].
Further, to determine the structure of our population,
we performed a multidimensional scaling based on 608
Table 4 Association analysis of SNPs with quantitative traits in control subjects in the initial phase
rs496888 rs6697733 rs945439 rs235249 rs17884213
Median (IQR) P Median (IQR) P Median (IQR) P Median (IQR) P Median (IQR) P
Trait AA/AG/GG TT/TC/CC TT/TC/CC TT/TC/CC GG/GA/AA
BMI 23.7 (20.4-27.0)
23.5 (20.0-26.6)
24.6 (22.4-29.0)
0.132 23.9 (20.5-26.9)
23.6 (20.2-26.9)
24.1 (20.2-27.6)
0.593 23.7 (20.4-26.7)
23.6 (20.3-27.0)
25.0 (21.8-28.0)
0.209 23.7 (20.4-26.9)
23.5 (20.3-26.9)
25.0 (21.7-27.8)
0.268 23.9 (20.4-27.2)
23.4 (20.3-26.4)
25.5 (21.6-28.2)
0.063
WHR 0.93 (0.87-0.98)
0.92 (0.86-0.98)
0.93 (0.87-0.98)
0.913 0.93 (0.87-0.98)
0.93 (0.87-0.99)
0.92 (0.86-0.97)
0.549 0.93 (0.87-0.98)
0.93 (0.86-0.99)
0.91 (0.87-0.97)
0.446 0.93 (0.87-0.98)
0.93 (0.86-0.99)
0.91 (0.87-0.97)
0.582 0.93 (0.86-0.98)
0.93 (0.87-0.99)
0.93 (0.87-0.97)
0.568
HbA1c 5.2 (4.9-5.6)
5.2 (4.9-5.6)
5.2 (4.9-5.3)
0.358 5.3 (4.9-5.6)
5.2 (4.9-5.5)
5.2 (4.8-5.5)
0.174 5.3 (4.9-5.6)
5.2 (4.9-5.5)
5.2 (4.8-5.5)
0.247 5.3 (4.9-5.6)
5.2 (4.5-5.5)
5.3 (4.9-5.5)
0.472 5.3 (4.9-5.6)
5.2 (4.9-5.6)
5.1 (4.9-5.5)
0.194
FPG 4.9 (4.5-5.3)
4.9 (4.5-5.2)
5.0 (4.3-5.3)
0.425 5.0 (4.5-5.3)
4.9 (4.5-5.2)
4.9 (4.5-5.2)
0.348 4.9 (4.5-5.3)
4.9 (4.5-5.2)
4.9 (4.5-5.2)
0.315 4.9 (4.5-5.3)
4.9 (4.5-5.2)
5.0 (4.6-5.2)
0.275 4.9 (4.5-5.3)
4.9 (4.5-5.2)
5.0 (4.6-5.2)
0.236
FPI 32.4 (16.8-56.4)
31.8 (18.6-60.0)
36.0 (21.0-67.2)
0.543 33.6 (17.4-61.2)
31.8 (18.0-54.0)
26.4 (16.2-43.2)
0.279 33.6 (17.4-60.6)
31.8 (18.6-54.0)
24.6 (15.6-41.4)
0.190 32.4 (16.8-59.4)
31.2 (18.6-54.0)
30.6 (15.6-51.0)
0.890 34.2 (18.0-59.4)
30.6 (17.4-54.0)
30.6 (17.4-44.4)
0.536
HOMA-IR 1.2 (0.6-2.0)
1.1 (0.6-2.0)
1.1 (0.7-2.4)
0.717 1.2 (0.6-2.2)
1.2 (0.6-1.9)
1.0 (0.6-1.5)
0.227 1.2 (0.6-2.2)
1.2 (0.6-1.9)
0.9 (0.5-1.4)
0.200 1.1 (0.6-2.1)
1.2 (0.6-1.9)
1.1 (0.6-1.9)
0.896 1.2 (0.6-2.2)
1.1 (0.6-1.9)
1.1 (0.6-1.5)
0.553
C-peptide 0.53 (0.36-0.73)
0.53 (0.40-0.76)
0.60 (0.43-0.79)
0.445 0.53 (0.40-0.76)
0.53 (0.36-0.73)
0.50 (0.33-0.63)
0.278 0.53 (0.40-0.76)
0.53 (0.36-0.73)
0.50 (0.33-0.60)
0.158 0.53 (0.40-0.76)
0.53 (0.36-0.76)
0.50 (0.33-0.63)
0.596 0.53 (0.40-0.76)
0.53 (0.36-0.73)
0.50 (0.40-0.66)
0.716
CRP 1.25 (0.59-2.67)
1.11 (0.58-2.57)
0.77 (0.37-1.64)
0.042 1.20 (0.58-2.48)
1.14 (0.58-2.86)
1.13 (0.66-2.78)
0.860 1.21 (0.57-2.52)
1.13 (0.59-2.87)
1.13 (0.70-2.54)
0.855 1.19 (0.55-2.48)
1.16 (0.60-2.93)
1.14 (0.75-2.84)
0.894 1.28 (0.57-2.70)
1.07 (0.57-2.43)
1.21 (0.71-3.35)
0.212
TC 4.42 (3.80-5.17)
4.42 (3.78-5.09)
4.14 (3.70-4.86)
0.408 4.42 (3.83-5.15)
4.37 (3.75-5.12)
4.34 (3.72-5.04)
0.605 4.4 (3.80-5.17)
4.37 (3.72-5.09)
4.42 (3.93-5.20)
0.532 4.4 (3.78-5.15)
4.4 (3.75-5.12)
4.4 (3.90-5.09)
0.986 4.40 (3.78-5.15)
4.42 (3.80-5.12)
4.27 (3.85-4.84)
0.636
HDL-C 1.06 (0.88-1.29)
1.06 (0.91-1.29)
1.09 (0.93-1.19)
0.857 1.06 (0.91-1.29)
1.06 (0.88-1.29)
1.11 (0.85-1.34)
0.947 1.06 (0.91-1.29)
1.06 (0.88-1.29)
1.09 (0.88-1.27)
0.899 1.06 (0.88-1.29)
1.06 (0.88-1.29)
1.06 (0.88-1.27)
0.938 1.06 (0.91-1.29)
1.09 (0.88-1.29)
1.03 (0.85-1.22)
0.637
LDL-C 2.82 (2.35-3.44)
2.79 (2.35-3.36)
2.66 (2.17-3.41)
0.775 2.82 (2.38-3.47)
2.74 (2.25-3.39)
2.77 (2.43-3.44)
0.338 2.82 (2.35-3.47)
2.74 (2.25-3.39)
2.74 (2.51-3.44)
0.293 2.82 (2.35-3.47)
2.79 (2.30-3.41)
2.74 (2.48-3.31)
0.814 2.79 (2.35-3.41)
2.84 (2.33-3.41)
2.64 (2.28-3.26)
0.699
TG 1.32 (0.98-1.84)
1.34 (0.98-1.83)
1.33 (1.05-1.77)
0.951 1.33 (0.98-1.86)
1.31 (0.96-1.76)
1.38 (1.11-1.73)
0.562 1.32 (0.97-1.9)
1.31 (0.97-1.74)
1.36 (1.11-1.73)
0.578 1.32 (0.96-1.86)
1.37 (1.01-1.76)
1.36 (1.11-1.81)
0.839 1.32 (0.96-1.86)
1.31 (0.99-1.77)
1.43 (1.06-1.75)
0.940
IQR: interquartile range. The P values were obtained by performing Kruskal-Wallis test.
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tion which clearly shows that the study population
belongs to one cluster (see Additional file 3). We have
also adjusted the associations for principal components
obtained from an ongoing genome wide association
study on the same study population and found that the
associations are not significant in either of the study
population, merging the two study populations or after
meta-analysis (data not presented). To take care of the
difference in allele frequency of rs945439, we have
meta-analyzed the data of the two study populations
both under random and fixed effect models, instead of
combining the two data sets.
Conclusion
The present two-stage association analysis did not detect
any association between type 2 diabetes and TNFRSF1B
genetic variants in Indo-Europeans from North India. The
results are consistent with our earlier observation of
no association of well-studied polymorphisms with type
2 diabetes in Indo-European population. Thus, we con-
clude, TNFESF1B is not a major genetic risk factor for type
2 diabetes in Indo-Europeans from North India.
Additional material
Additional file 1: Schematic presentation of selection of SNPs for
the study and linkage disequilibrium pattern around TNFRSF1B
gene in GIH population. A figure described the linkage disequllibrium
between the SNPs, drawn using the GIH population data from HapMap
3. The arrow above the SNPs in LD plot shows the SNPs that have been
genotyped. * These SNPs were genotyped in our previous study (Ref).
Arrows with dotted pattern lines shows the SNPs not presented in LD
plot as these were not available in HapMap 3.
Additional file 2: Hardy Weinberg Equilibrium in cases and control
subjects in initial phase and replication phase for all the SNPs.A
table summarized the minor allele frequencies and Hardy Weinberg
Equilibrium of the SNPs in cases and control subjects. MAF: Minor allele
frequency; P_HWE: P value for Hardy Weinberg Equilibrium; NA: Not
genotyped in replication phase.
Additional file 3: ³Multidimensional scaling based on markers
genotyped in our initial study². A figure presented the
multidimensional scaling based on 608 unlinked markers (r2 < 0.20) that
were used to obtain the positions on the first and second dimensions
using PLINK for the samples of the initial phase.
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